Results 41 to 50 of about 519,893 (158)

The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5

Vaccines, 2023
The aim of this study is to investigate the reactogenicity and immunogenicity of the fourth dose using monovalent mRNA vaccines after different three-dose regimens and to compare the 30 µg BNT162b2 and 50 µg mRNA-1273 vaccines.
Sitthichai Kanokudom, Jira Chansaenroj, Nungruthai Suntronwong, Suvichada Assawakosri, Ritthideach Yorsaeng, Pornjarim Nilyanimit, Ratchadawan Aeemjinda, Nongkanok Khanarat, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Thanunrat Thongmee, Donchida Srimuan, Thaksaporn Thatsanathorn, Natthinee Sudhinaraset, Nasamon Wanlapakorn, Sittisak Honsawek, Yong Poovorawan   +16 more
doaj   +1 more source

Table1_Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines.xlsx

, 2023
ImportanceThere is a high level of public and professional interest related to potential safety issues of the COVID-19 vaccines; however, no serious adverse cardiovascular events were reported in phase 3 randomized controlled trials of their safety and ...
Pasquale Sessa (17445048), Kristian Hay Kragholm (13174425), Francesco Sessa (2817850), Paolo Polverino (10897845), Maurizio Sessa (3146397), Manan Pareek (738565)   +5 more
core   +1 more source

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines

Human Vaccines & Immunotherapeutics, 2023
Certain aspects of the immunogenicity and effectiveness of the messenger ribonucleic acid (mRNA) vaccines (mRNA-1273 and BNT162b2) developed in response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are still ...
Thomas E. Hickey, Troy J. Kemp, Jimmie Bullock, Aaron Bouk, Jordan Metz, Abigail Neish, James Cherry, Douglas R. Lowy, Ligia A. Pinto   +8 more
doaj   +1 more source

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS

International Journal of Infectious Diseases, 2023
Intro: The US CDC recommends that COVID-19 vaccines may be coadministered with other age-appropriate vaccines. There is limited data assessing outcomes, including reactogenicity, on such co-administration.
A. Naficy, P. Pirrotta, A. Kuxhausen, J. Miller, B. Leav, A. Mwakingwe-Omari   +5 more
doaj   +1 more source

Breakhthrough Infection Pasca Pemberian Booster mRNA Heterolog pada Tenaga Kesehatan di RSUD Arifin Achmad

Majalah Kedokteran Andalas, 2023
Tujuan: Mengetahui prevalensi dan karakteristik responden breakthrough infection pada tenaga kesehatan di RSUD Arifin Achmad Provinsi Riau dalam 14 hari – 6 bulan pasca vaksinasi booster mRNA-1273. Metode: Metode penelitian cross sectional yang dilakukan
Dina Br Nababan, Eka Bebasari, Ligat Pribadi Sembiring, Dani Rosdiana, Rahmat Azhari Kemal   +4 more
doaj   +1 more source

Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients

, 2022
ImportanceIn patients with hematologic malignancies, the immunogenicity of the standard 2-dose mRNA-1273 coronavirus disease 19 (COVID-19) vaccination schedule is often insufficient due to underlying disease and current or recent therapy.
Haggenburg, S., Kater, A. P., van Gils, M. J., van Leeuwen, E. M. M., Beaumont, T., Hofsink, Q., Broers, A. E. C., van Binnendijk, R. S., Haverkate, N. J. E., Burger, J. A., Mutsaers, P. G. N. J., Smits, G. P., van Doesum, J. A., Kootstra, N. A., Heemskerk, M. H. M., Bontkes, H. J., Lissenberg-Witte, B. I., Hazenberg, M. D., Goorhuis, A., Wouters, D., van Meerten, T., Bhoekhan, M. S., Nijhof, I. S., Bouhuijs, J. H., Groen, K., den Hartog, G., Zweegman, S., Rutten, C. E.   +27 more
core   +1 more source

Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults

Human Vaccines & Immunotherapeutics, 2023
This interim analysis of an ongoing phase 1 randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein (i.e ...
Patrick Yassini, Mark Hutchens, Yamuna D. Paila, Lorraine Schoch, Anne Aunins, Uma Siangphoe, Robert Paris   +6 more
doaj   +1 more source

Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination

, 2022
Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy We longitudinally profiled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)–specific serological and memory B cell (MBC ...
Normark, Johan, Garcia, Marina,, Ackerman, Margaret E.,, Ahlm, Clas,, Johnson, Carl E.,, Ahlm, Clas, Christ, Wanda, Normark, Johan,, Walker, Laura M.,, Walker, Laura M., Klingström, Jonas, Kaku, Chengzi I.,, Champney, Elizabeth R.,, Klingström, Jonas,, Kaku, Chengzi I., Christ, Wanda,, Johnson, Carl E., Sakharkar, Mrunal, Sakharkar, Mrunal,, Forsell, Mattias N. E.,, Garcia, Marina, Ackerman, Margaret E., Forsell, Mattias N. E., Champney, Elizabeth R.   +23 more
core   +1 more source

Attenuated activation of pulmonary immune cells in mRNA-1273–vaccinated hamsters after SARS-CoV-2 infection

, 2021
The mRNA-1273 vaccine is effective against SARS-CoV-2 and was granted emergency use authorization by the FDA. Clinical studies, however, cannot provide the controlled response to infection and complex immunological insight that are only possible with ...
Mire, Chad E., Chen, Xi, Periasamy, Sivakumar, Bock, Kevin W., Wang, Yuan, Troyanskaya, Olga G., Carfi, Andrea, Woods, Angela, Zaslavsky, Elena, Rubenstein, Aliza B., Pietzsch, Colette, Ramos, Irene, Shi, Pei-Yong, Ma, LingZhi, Graham, Barney S., Minai, Mahnaz, Sealfon, Stuart C., Ramanathan, Palaniappan, Meyer, Michelle, Ge, Yongchao, Cheng, Wan Sze, Edwards, Darin, Smith, Gregory R., Nagata, Bianca M., Bukreyev, Alexander, Henry, Carole, Stewart-Jones, Guillaume B.E., Moore, Ian N.   +27 more
core   +1 more source

Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)

International Journal of Infectious Diseases
Objectives: To assess the safety and immunogenicity of a fourth vaccination (second booster) in individuals aged ≥75 years. Methods: Participants were randomized to BNT162b2 (Comirnaty, 30 µg) or messenger RNA (mRNA)-1273 (Spikevax, 100 µg).
Jannik Stemler, Lusine Yeghiazaryan, Christoph Stephan, Kristin Greve-Isdahl Mohn, Antonio-José Carcas-Sansuan, Esperanza Romero Rodriguez, José Moltó, Itziar Vergara Mitxeltorena, Tobias Welte, Birutė Zablockienė, Murat Akova, Ullrich Bethe, Sarah Heringer, Jon Salmanton-García, Julia Jeck, Lea Tischmann, Marouan Zarrouk, Arnd Cüppers, Lena M. Biehl, Jan Grothe, Sibylle C. Mellinghoff, Julia A. Nacov, Julia M. Neuhann, Rosanne Sprute, Jesús Frías-Iniesta, Riya Negi, Colette Gaillard, Gurvin Saini, Alejandro García León, Patrick W.G. Mallon, Christine Lammens, An Hotterbeekx, Katherine Loens, Surbhi Malhotra-Kumar, Herman Goossens, Samir Kumar-Singh, Franz König, Martin Posch, Philipp Koehler, Oliver A. Cornely   +39 more
doaj   +1 more source